We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Alseres Pharmaceuticals Inc (CE) | USOTC:ALSE | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.005 | 0.00 | 00:00:00 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No.__9___ )*
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[x] Rule 13d-1(b)
[] Rule 13d-1(c)
[] Rule 13d-1(d)
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 021152103 -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON(S) S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON(S) INGALLS & SNYDER LLC 13-5156620 -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] -------------------------------------------------------------------------------- 3. SEC USE ONLY -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION NEW YORK STATE -------------------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 6. SHARED VOTING POWER EACH 0 REPORTING -------------------------------------------------------------- PERSON 7. SOLE DISPOSITIVE POWER WITH 0 -------------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 100,000 -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 100,000 -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.0% -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON* BD, IA -------------------------------------------------------------------------------- Item 1. (a) Name of Issuer: ALSERES PHARMACEUTICALS, INC. -------------------------------------------------------------- (b) Address of Issuer's Principal Executive Offices: 239 SOUTH STREET HOPKINTON, MA 01748 -------------------------------------------------------------- Item 2. (a) Name of Person Filing: INGALLS & SNYDER LLC -------------------------------------------------------------- (b) Address of Principal Business Office, or if None, Residence: 61 BROADWAY, NEW YORK, NY 10006 -------------------------------------------------------------- (c) Citizenship: NEW YORK STATE -------------------------------------------------------------- (d) Title of Class of Securities: COMMON STOCK -------------------------------------------------------------- (e) CUSIP Number: 021152103 -------------------------------------------------------------- Item 3. If this statement is filed pursuant to Rules 240.13d-(1), or 13d-2(b) or (c), check whether the person filing is a: (a) [X] Broker or Dealer registered under Section 15 of the Act, (15 U.S.C 78o) (b) [ ] Bank as defined in Section 3(a)(6) of the Act, (15 U.S.C 78c) (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act, (15 U.S.C 78c) (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8) (e) [X] Investment Adviser in accordance with Section 240.13d-1(b)(1)(ii)(E) (f) [ ] Employee Benefit Plan or endowment fund in accordance to Section 240.13d-1(b)(ii)(F) (g) [ ] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G) (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C 1813) (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C 80a-3) (j) [ ] Group, in accordance with Section 240.13d-1(b)(1)(ii)(J) Item 4. Ownership. (a) Amount beneficially owned: 100,000----------, (b) Percent of class: 0.0%----------------------, (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote 0--, (ii) Shared power to vote or to direct the vote 0------, (iii) Sole power to dispose or to direct the disposition of 0-----, (iv) Shared power to dispose or to direct the disposition of 100,000------ Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ]. INAPPLICABLE Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Securities reported under Shared Dispositve Power include securities owned by clients of Ingalls & Snyder LLC ("Ingalls"), a registered broker dealer and a registered investment advisor, in accounts managed under investment advisory contracts. All shares reported assume the exercise of all warrants owned by Gipson. Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company. INAPPLICABLE Item 8. Identification and Classification of Members of the Group. INAPPLICABLE Item 9. Notice of Dissolution of Group. INAPPLICABLE Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: 01/25/13 BY: Ingalls & Snyder, LLC /s/ THOMAS O. BOUCHER, JR ---------------------------------- (Signature)* THOMAS O. BOUCHER, JR ---------------------------------- Managing Director (Name/Title) |
1 Year Alseres Pharmaceuticals (CE) Chart |
1 Month Alseres Pharmaceuticals (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions